The introduction of tumor necrosis factor inhibitors has led to a paradigm shift in the
management of inflammatory bowel disease (IBD). The subsequent introduction of both anti …

Introduction The STRIDE consensus suggested to focus on mucosal healing, based on
biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This …

Background The exposure-response relationship is less established for adalimumab (ADA)
compared with infliximab in inflammatory bowel disease (IBD). Evidence supporting …

Comprehensive Summary The binding of Sphingosine‐1‐phosphate (S1P) with the S1PR1‐
5 plays a fundamental physiological role in a number of processes including vascular …

Background The optimal infliximab dose intensification strategy to address loss of response
associated with subtherapeutic infliximab trough levels remains uncertain, as does whether …

Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on
intravenous infliximab require dose intensification. Accessing additional intravenous …

Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis ‐ it depends on how
you use the drug Page 1 140 | wileyonlinelibrary.com/journal/apt Aliment Pharmacol Ther …

Reply. We thank Drs Gajendran et al for their interest in our recent study. 1 We re-emphasize
that this was a study using real-life data, describing the treatment patterns after variceal …

Background The optimal infliximab dose intensification strategy to address secondary loss of
response (LOR) remains unclear. This study aimed to compare clinical and pharmacokinetic …

Background: New point-of-care (POC) techniques offer rapid results and address some of
the limitations of traditional enzyme-linked immunosorbent assay (ELISA) methods, such as …